Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Apitoria Pharma’s API manufacturing facility classified as VAI by USFDA
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 m
The European regulator will conduct a re-inspection of the facility to verify the compliance
Standalone profit from operations for Q4-2024 were Rs. 108 crore
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
the inspection conducted from January 27 to January 31, 2025
This rating reflects Lupin's leadership in environmental transparency and performance
Subscribe To Our Newsletter & Stay Updated
